EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma

Erin McGillivray iD, Karam Ashouri, Eftychia Chatziioannou iD, Jesús Antonio Ocejo Gallegos, Jabra Zarka, Jacob Kechter, Angelina S Hwang iD, Kevin Zhang, Milton Barros, Justin Yeh, Ian Okazaki, Andrew B Crocker und 32 weitere

British Journal of Dermatology · 2025

DOI: 10.1093/bjd/ljae401 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Erin McGillivray und 43 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, USC Keck School of Medicine, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Skin Neoplasms, Melanoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Combination immune checkpoint blockade targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) leads to high response rates and improved survival in patients with advanced cutaneous melanoma (CM). Less is known about the efficacy of this combination in acral lentiginous melanoma (ALM).

Objectives

To determine the efficacy of combination immune checkpoint blockade targeting PD-1 and CTLA-4 in a diverse, real-world population of patients with ALM.

Methods

This multi-institutional retrospective study analysed patients with histologically confirmed ALM treated with a combination of PD-1 and CTLA-4 inhibitors between 2010 and 2022. The primary objective of the study was the objective response rate (ORR) as per the RECIST criteria. The secondary objectives were progression-free survival (PFS) and overall survival (OS).

Results

In total, 109 patients with advanced ALM treated with combined PD-1 and CTLA-4 blockade in any line of treatment were included. The majority of patients had stage IV disease (n = 81; 74.3%). The ORR for the entire cohort was 18.3% [95% confidence interval (CI) 11.6–26.9], with 9 (8.3%) complete and 11 (10.1%) partial responses. A further 22 patients (20.2%) had stable disease, and the disease control rate was 38.5%. Median PFS was 4.2 months (95% CI 3.25–5.62), while median OS was 17 months (95% CI 12.4–23.1). Ninety-five patients (87.2%) had a treatment-related adverse event, with 40.4% (n = 44/109) experiencing at least one grade 3 or 4 toxicity. Elevated lactate dehydrogenase (P = 0.04), ≥ 2 lines of prior treatment (P = 0.03) and Asian ethnicity (P = 0.04) were associated with worse OS, while Hispanic/Latino ethnicity was associated with better OS (P = 0.02).

Conclusions

Combination PD-1 and CTLA-4 blockade is less effective for ALM than for CM, despite similar toxicity. In particular, Asian patients appear to derive less benefit from this regimen. Novel treatment approaches are needed for this rare melanoma subtype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CTLA-4 AntigenProgrammed Cell Death 1 ReceptorSkin NeoplasmsMelanomaImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleRetrospective StudiesMiddle AgedAgedAdultAged, 80 and overProgression-Free SurvivalTreatment OutcomeYoung Adult

Substanzen

CTLA-4 AntigenProgrammed Cell Death 1 ReceptorCTLA4 protein, humanPDCD1 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, USC Keck School of Medicine, Los Angeles, CA, USA.
  • Division of Oncology, USC Keck School of Medicine, USC Norris Cancer Hospital, Los Angeles, CA, USA.

ORCID-Profile: Erin McGillivray, Eftychia Chatziioannou, Angelina S Hwang, Takuya Maeda

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health
  • National Cancer Institute

Zitieren

APA

McGillivray, E., Ashouri, K., Chatziioannou, E., Gallegos, J. A. O., Zarka, J., Kechter, J., Hwang, A. S., Zhang, K., Barros, M., Yeh, J., Okazaki, I., Crocker, A. B., Maeda, T., Park, S. J., Choi, J., Andreoli, M., Darwish, T., Savage, D. J., Kim, K. B., …, & In, G. K. (2025). Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae401

Vancouver

McGillivray E, Ashouri K, Chatziioannou E, Gallegos JAO, Zarka J, Kechter J, et al. Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljae401

BibTeX
@article{McGillivray2025,
  author = {McGillivray, Erin and Ashouri, Karam and Chatziioannou, Eftychia and Gallegos, Jesús Antonio Ocejo and Zarka, Jabra and Kechter, Jacob and Hwang, Angelina S and Zhang, Kevin and Barros, Milton and Yeh, Justin and Okazaki, Ian and Crocker, Andrew B and Maeda, Takuya and Park, Soo J and Choi, Jacob and Andreoli, Mia and Darwish, Tarneem and Savage, David J and Kim, Kevin B and Gupta, Jayant and Shen, James and Shirai, Keisuke and Choi, April and Pai, Lori and Vazquez, Vinicius de Lima and Moser, Justin and Amaral, Teresa and Hernandez Aya, Leonel F and Lutzky, Jose and Najjar, Yana G and Costello, Collin M and Mangold, Aaron R and Bhatia, Shailender and Gibney, Geoffrey T and Farma, Jeffrey M and Daniels, Gregory A and Sosman, Jeffrey and Chandra, Sunandana and Mangla, Ankit and Bollin, Kathryn and Possik, Patrícia Abrão and Robles-Espinoza, Carla Daniela and Ito, Fumito and In, Gino K},
  title = {Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma},
  journal = {British Journal of Dermatology},
  year = {2025},
  doi = {10.1093/bjd/ljae401}
}
Kostenlos starten →